|
Petvivo Holdings Inc (NASDAQ: PETV) |
|
|
|
|
Select the Financial Report:
|
|
Select the Period:
|
|
Description of Petvivo Holdings Inc's Business Segments
Petvivo Holdings Inc. is a company focused on the development and commercialization of innovative products and technologies primarily in the veterinary field, particularly relating to the treatment of orthopedic joint ailments in animals. The company leverages advanced biomaterial technologies through strategic partnerships and its wholly-owned subsidiary, Gel-Del Technologies, to create effective medical solutions. Here is an extensive overview of the companys segments, products, and services:
Segments
1. Veterinary Medicine:
- Petvivo is focused on applying advanced biomaterials in the treatment of various veterinary conditions, particularly orthopedic issues like osteoarthritis and joint injuries in animals.
2. Biomaterials Development:
- Through Gel-Del, Petvivo explores the potential of protein-based biomaterials and devices that replicate the bodys tissues. This segment emphasizes long-term implantation and therapeutic efficacy for both animals and potential future applications in human medicine.
3. Medical Device Manufacturing:
- The company is involved in utilizing proprietary materials for the development of medical devices intended for veterinary and potential human applications, showcasing an integrated approach to biomaterial research and production.
Products and Technologies
Petvivos portfolio includes a range of advanced products designed to enhance the therapeutic options available for treating animal health conditions, particularly in orthopedics:
1. Orthopedic Products:
- KuuR': A proprietary veterinary device designed to treat osteoarthritis in companion animals. Utilizing a unique formulation, KuuR' offers pain relief and improved mobility by enhancing joint function.
- OrthoGelic' and OrthoMetic': These products are focused on difficult-to-heal bone fractures and orthopedic issues. They employ a biomaterial designed to mimic bone structure, promoting healing and integration while preventing non-bone tissue infiltration.
2. Dermal Technologies:
- While primarily focused on veterinary applications, the biomaterials developed are also applicable for human dermal filler purposes, such as the CosmetaLife'. This technology offers wrinkle reduction through injectable gel particles that rejuvenate dermal tissue.
3. Cardiovascular Products:
- The blood-compatible biomaterial developed by Gel-Del includes the VasoGraft', a vascular graft designed to facilitate cardiovascular repair. This product embodies qualities that mitigate clotting and promote blood compatibility.
4. Drug Delivery Systems:
- Petvivo also explores drug delivery technologies. Their fabrication techniques allow for the precise distribution of therapeutics via coatings and implantable devices, which could include products such as OraPatch' for transmucosal delivery, enhancing drug absorption.
Services
1. Research and Development:
- Petvivo emphasizes R&D in both the veterinary and medical device sectors. The company continually seeks to innovate and refine its offerings through research, clinical trials, and partnerships, particularly with Gel-Del, which specializes in developing and manufacturing biomaterials.
2. Regulatory Support:
- The company also has expertise in navigating the regulatory pathways necessary for the approval of veterinary and medical devices, ensuring compliance with veterinary health standards and potentially human medical regulations in the future.
3. Partnership and Collaboration:
- Through agreements and collaborations, particularly with Gel-Del Technologies, Petvivo aims to expand its technological capabilities and market reach in both animal health and broader medical applications.
Conclusion
Petvivo Holdings Inc. represents a dynamic intersection of veterinary medicine and advanced biomaterials technology. With its proprietary products aimed at alleviating orthopedic conditions in animals, and ongoing collaboration with Gel-Del, Petvivo is positioned to lead in innovative treatment solutions within the veterinary sector. Through its range of products and dedicated services, the company is committed to improving animal health outcomes while exploring future applications in the medical technology space.
(Dec 31 2024) three months ended Q3
|
| Business Segments |
Revenues
(in millions $) |
Income
(in millions $) |
%
(Profit Margin) |
| Total |
0.58 |
-1.76 |
- |
(Dec 31 2024) three months ended Q3
|
| Revenue Growth rates by Segment |
Y/Y Revenue
% |
Q/Q Revenue
% |
| Total |
181.3 % |
190.61 % |
(Dec 31 2024) three months ended Q3
|
| Income Growth rates by Segment |
Y/Y Income
% |
Q/Q Income
% |
| Total |
- |
- |
|
|
